期刊文献+

血小板Ⅱb/Ⅲa受体拮抗剂联合药物洗脱支架治疗急性心肌梗死临床观察

Observation of the effect of homemade tirofiban combined with the drug eluting stent on the treatment of acute myocardial infarction
原文传递
导出
摘要 目的探讨血小板Ⅱb/Ⅲa受体拮抗剂——替罗非班(欣维宁)联合药物洗脱支架治疗急性心肌梗死(AMI)的安全性和有效性。方法因AMI行经皮腔内冠状动脉介入(PCI)治疗的患者52例,于置入药物洗脱支架前予国产替罗非班(欣维宁)负荷量后,以维持量持续静脉泵入48h,观察手术成功率、围手术期出血血栓并发症及1~3个月的主要心脏不良事件(包括死亡,靶血管再次重建术)和出血发生。结果52例患者PCI均取得成功,手术成功率100%,无严重出血并发症,无急性、亚急性血栓及慢血流发生。治疗无死亡,无再发心梗及靶血管再次血运重建,围手术期血小板聚集率明显降低。结论欣维宁联合药物洗脱支架行急诊PCI治疗急性心肌梗死安全有效,不增加出血危险性,可明显降低围手术期及近期并发症。 Objective To evaluate the safety and efficiency of homemade tirofiban combined with drug-eluting stent in the treatment of acute myocardial infarction. Methods Fifty-two cases of myocardial infarction patients were used the load dose homemade tirofiban (Xinweining) before the pereutanenous coronary interventions ( PCI ), then pumped for 48 hours with the sustaining dose. The success rate of operations, peri-operational bleeding and thrombosis complications and main adverse cardiac events were observed, the platelet aggregation rate was monitored. Results Fifty-two patients were all performed PCI successfully, the success rate of operation was 100 %, there were no serious bleeding complications, acute or subaeute intra-stent thrombosis and slow reflow phenomenon occurred. There were no re-infarction and target vascular reperfusion occurred. The platelet aggregation rate were obviously decreased during peri-operation. Conclusion Homemade tirofiban combined with drug-eluting stent, which is safety and efficiency in the treatment of acute myocardial infarction, can obviously decrease the complications of perioperation and short term.
出处 《中国基层医药》 CAS 2007年第2期205-206,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 心肌梗死 血管成形术 经腔 经皮冠状动脉 替罗非班 支架 Myocardial infarction Angioplasty, transluminal, pereutanenous coronary Tirofiban Stents
  • 相关文献

参考文献5

二级参考文献7

  • 1曲海波,李占全,高阳,张明,袁龙.冠状动脉药物洗脱支架内顽固性亚急性血栓形成一例[J].中国介入心脏病学杂志,2004,12(4):217-217. 被引量:10
  • 2[1]Peerlinck K,De Lepeleire I,Goldberg M,et al.MK-383(L-700,46 2),a selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa antagonist,is active in man[J].Circulation,1993,88(4,Part1)∶1512-1517.
  • 3[2]Joseph J,Lynch JR,Jacquelynn JC,et al.Nonpeptide glycoprotein Ⅱb/Ⅲa inhibitors.5.antithrombotic effects of MK-0383[J].J Pharmacol Exp Ther ,1995,272(1)∶20-32.
  • 4[3]FDA.MERCK&CO.,INC.West Point,PA 19486,USA [EB/OL].http://www.fda.gov/cd er/foi/label/1998/20913lbl.pdf.2000-08-15.
  • 5[4]FDA.NDA#20-912 Aggrastat Medical/Stastical Review [EB/OL].http://www.f da.gov/cardiovascular and renal drugs advisory committee.html.1998-02-15.
  • 6[5]Alexander JH,Harrington RA.Recent antiplatelet drug trails in the acute c ornary syndromes[J].Drugs,1998,56(6)∶965-976.
  • 7[6]McClellan KJ,Goa KL.Tirofiban[J].Drugs,1998,56(6)∶1067- 1080.

共引文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部